The outcome of macroprolactinomas resistant to dopamine agonists

The outcome of macroprolactinomas resistant to dopamine agonists

Aim: The present study aims to assess the final outcome after combined therapeutic approaches in patients with macroprolactinoinas resistant to dopamine agonists (DA). Patients: Records of patients with macroprolactinoma hospitalized in the Institute of Endocrinology, Bucharest, between 1978-2005, w...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Coculescu, M, Anghel, R, Trifanescu, R, Voicu, D, Karavitaki, N, Wass, J
Natura:	Journal article
Lingua:	English
Pubblicazione:	2005

Documenti analoghi

Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
di: Barber, T, et al.
Pubblicazione: (2011)

Prospective Assessment of Pituitary Function in Patients with Macroprolactinoma Treated with Cabergoline.
di: Karavitaki, N, et al.
Pubblicazione: (2010)

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
di: Karavitaki, N, et al.
Pubblicazione: (2013)

Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
di: Karavitaki, N, et al.
Pubblicazione: (2013)

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
di: Grossman, A, et al.
Pubblicazione: (1987)

Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
di: Lambert, K, et al.
Pubblicazione: (2017)

Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes
di: Lambert, K, et al.
Pubblicazione: (2017)

The modern management of macroprolactinomas.
di: Grossman, A
Pubblicazione: (1991)

Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
di: Turner, H, et al.
Pubblicazione: (1999)

The effect of dopamine agonist therapy on large functionless pituitary tumours.
di: Grossman, A, et al.
Pubblicazione: (1985)

Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features.
di: Suliman, S, et al.
Pubblicazione: (2007)

A case of macroprolactinoma encasing an internal carotid artery aneurysm, presenting as pituitary apoplexy.
di: Soni, A, et al.
Pubblicazione: (2008)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke.
di: Gorgoraptis, N, et al.
Pubblicazione: (2012)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke
di: Gorgoraptis, N, et al.
Pubblicazione: (2012)

Outcome in surgically treated Rathke's cleft cysts: long-term monitoring needed.
di: Trifanescu, R, et al.
Pubblicazione: (2011)

Dopamine agonists and risk: impulse control disorders in Parkinson's disease.
di: Voon, V, et al.
Pubblicazione: (2011)

Dopamine agonists and risk: Impulse control disorders in Parkinson's; Disease
di: Voon, V, et al.
Pubblicazione: (2011)

Rathke's cleft cysts.
di: Trifanescu, R, et al.
Pubblicazione: (2012)

Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s
di: McIntosh, E, et al.
Pubblicazione: (2021)

MORPHINE-INDUCED HYPERACTIVITY IN RATS IS ENHANCED BY THE SELECTIVE D2 DOPAMINE ANTAGONIST RACLOPRIDE AND BLOCKED BY DOPAMINE AGONISTS
di: Oneill, M, et al.
Pubblicazione: (1990)

The effect of the dopamine agonist, apomorphine, on regional cerebral blood flow in normal volunteers.
di: Grasby, P, et al.
Pubblicazione: (1993)

Two new dopamine agonists that are long acting in vivo but short acting in vitro.
di: Grossman, A, et al.
Pubblicazione: (1980)

PROLACTINOMA IN A PREPUBERTAL CHILD - RESPONSE TO SURGERY, RADIOTHERAPY AND DOPAMINE AGONIST THERAPY
di: Sinn, D, et al.
Pubblicazione: (1985)

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
di: Karavitaki, N, et al.
Pubblicazione: (2005)

Acute octreotide suppression test (100 mu g sc): a valuable tool for predicting the long-term response to the long-acting somatostatin analogs in patients with active acromegaly
di: Karavitaki, N, et al.
Pubblicazione: (2005)

Long-term motor stimulant effects of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO), a dopamine D-2 receptor agonist: interactions with a dopamine D-1 receptor antagonist and agonist.
di: Martin-Iverson, M, et al.
Pubblicazione: (1988)

Two new dopamine agonists that are long acting in vivo but short acting in vitro
di: Grossman, A, et al.
Pubblicazione: (1980)

DIFFERENTIAL-EFFECTS OF D-1 AND D-2 DOPAMINE AGONISTS IN MPTP-TREATED SQUIRREL-MONKEYS
di: Boyce, S, et al.
Pubblicazione: (1990)

Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy.
di: Stoessl, A, et al.
Pubblicazione: (1989)

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
di: Verhelst, J, et al.
Pubblicazione: (1991)

Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
di: Ciccarelli, E, et al.
Pubblicazione: (1988)

An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine.
di: Fray, P, et al.
Pubblicazione: (1980)

Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
di: Karavitaki, N, et al.
Pubblicazione: (2006)

Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization.
di: Martin-Iverson, M, et al.
Pubblicazione: (1988)

Modulation of dopamine release in the nucleus accumbens by 5-HT1B agonists: involvement of the hippocampo-accumbens pathway.
di: Boulenguez, P, et al.
Pubblicazione: (1996)

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
di: Mafham, M, et al.
Pubblicazione: (2018)

Enhanced taste recognition following subacute treatment with the dopamine D2/D3 receptor agonist pramipexole in healthy volunteers
di: Kaltenboeck, A, et al.
Pubblicazione: (2022)

The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly.
di: Karavitaki, N, et al.
Pubblicazione: (2009)

Acromegaly: Treatment with somatostatin analogs
di: Karavitaki, N, et al.
Pubblicazione: (2005)

Pegvisomant: a new treatment modality for acromegaly.
di: Karavitaki, N, et al.
Pubblicazione: (2004)